BCY 3814 / Bicycle Therap - LARVOL DELTA

Bicycle Therapeutics to present immune oncology CD137 data on multivalent and tumour-targeted bispecific bicycles at Peptides Congress (Businesswire) - "Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that Punit Upadhyaya, Ph.D., Senior Scientist at Bicycle, will present at the 6th Annual Peptides Congress in London. The presentation, entitled 'Bicycles as T-cell Modulators: Activation of CD137 Using Multivalent and Tumour-targeted Bicycle Peptides,' will take place on Thursday, April 25, at 12:00 BST."

Preclinical

Activation of CD137 using multivalent and tumor targeted Bicyclic peptides (AACR 2019) - "...Two human anti-CD137 antibodies, urelumab and utomilumab are currently undergoing clinical testing...We hypothesized that fully synthetic Bicycle CD137 agonists with rapid clearance, minimal liver exposure and no Fc receptor interaction may induce CD137 mediated anti-tumor activity while avoiding liver toxicity.A high affinity lead BCY3814 (KD ~30 nM) that binds to the CD137 ligand-binding site was identified...Selected CD137 multimers and heterotandems are being tested further in humanized mouse models for T cell activation, anti-tumor activity, and liver safety. These molecules are promising, novel cancer immunotherapy candidates and importantly, they pave the way for development of synthetic agonists of other TNF receptors that can be targeted to the local tumor microenvironment."

IO Biomarker